TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15489847

Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 150
Study: 11292962

Group type: EXPERIMENTAL
Intervention: Combination of alpha tocopherol, rutin, melilotus officinalis, and centella asiatica (oral administration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 9733230

Group type: EXPERIMENTAL
Intervention: 18 g fish oil concentrate (6.4 g eicosapentaenoic acid and 3.9 g docosahexaenoic acid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 18 g placebo
Number of subjects: 18
Study: 8180533

Group type: EXPERIMENTAL
Intervention: Reciprocal ST depression
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Isolated ST depression
Number of subjects: 202
Study: 2514324

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 24
Study: 30075709

Group type: EXPERIMENTAL
Intervention: Attribution retraining combined with exercise class
Number of subjects: 572

Group type: COMPARATOR
Intervention: Generic health education (control)
Number of subjects: 572
Study: 25411324

Group type: EXPERIMENTAL
Intervention: Reverse regression approach for handling nonignorable missingness
Number of subjects: 0
Study: 25012174

Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg once daily for 6 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eplerenone 150 mg once daily for 6 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amiloride 20 mg once daily for 6 weeks
Number of subjects: 30
Study: 24176099

Group type: EXPERIMENTAL
Intervention: Haemofiltration during bypass (experimental group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No haemofiltration during bypass (control group)
Number of subjects: 37
Study: 21167341

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 8771

Group type: EXPERIMENTAL
Intervention: Female sex (propensity-matched analysis)
Number of subjects: 8771
Study: 19045971

Group type: EXPERIMENTAL
Intervention: Coping and communication-enhancing intervention (CCI)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Supportive counseling (SC)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 353
Study: 15983451

Group type: EXPERIMENTAL
Intervention: 0.0% end‐tidal sevoflurane (awake state)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1.0% end‐tidal sevoflurane (light state)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2.0% end‐tidal sevoflurane (deep state)
Number of subjects: 6
Study: 12771261

Group type: EXPERIMENTAL
Intervention: Intranasal drug administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous drug administration
Number of subjects: 8
Study: 10551650

Group type: COMPARATOR
Intervention: Neoral 5 mg/kg BDS
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.05 mg/kg BDS
Number of subjects: 64
Study: 8681162

Group type: EXPERIMENTAL
Intervention: Submaximal orientation session
Number of subjects: 266

Group type: COMPARATOR
Intervention: Nonoriented subjects
Number of subjects: 266
Study: 1948126

Group type: EXPERIMENTAL
Intervention: rIFN alpha 2b combined with VBMCP chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study: 6832208

Group type: EXPERIMENTAL
Intervention: 5 mg/kg dose of caffeine as an aqueous oral solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5 mg/kg dose of caffeine as an intravenous infusion
Number of subjects: 10
Study: 31378600

Group type: EXPERIMENTAL
Intervention: rTMS (8 sessions targeting the left dorsolateral prefrontal cortex over 4 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 43
Study: 28948296

Group type: EXPERIMENTAL
Intervention: GIP(3-30)NH2 (800 pmol kg-1 min-1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GIP (1.5 pmol kg-1 min-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GIP(3-30)NH2 alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GIP with or without GIP(3-30)NH2
Number of subjects: 10
Study: 26302817

Group type: EXPERIMENTAL
Intervention: 80 mL double-balloon catheter
Number of subjects: 98

Group type: COMPARATOR
Intervention: 30 mL single-balloon catheter
Number of subjects: 98
Study: 25015214

Group type: EXPERIMENTAL
Intervention: DSEK
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: PK
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: DLEK
Number of subjects: 63

Group type: COMPARATOR
Intervention: All treatments (PK, DLEK, DSEK)
Number of subjects: 63
Study: 22354616

Group type: EXPERIMENTAL
Intervention: Culturally tailored motivational interviewing intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 16
Study: 20600555

Group type: COMPARATOR
Intervention: Distilled water immersion for 24 hours at 37 degrees C (baseline measurement)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Distilled water immersion for 1 week, 1 month, or 3 months at 37 degrees C or 60 degrees C
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 0.01 mol/L lactic acid immersion for 1 week, 1 month, or 3 months at 37 degrees C or 60 degrees C
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 50% ethanol immersion for 1 week, 1 month, or 3 months at 37 degrees C or 60 degrees C
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Nexus 2 and Rely X Veneer
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Rely X Luting 2
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Resin luting cements vs RM-GICs
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Panavia F and Set vs RM-GICs
Number of subjects: 114
Study: 17469693

Group type: COMPARATOR
Intervention: Cholinesterase inhibitors (e.g., rivastigmine, donepezil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study: 17310311

Group type: EXPERIMENTAL
Intervention: Combination of CPAP and 100 mg sildenafil on demand for intercourse
Number of subjects: 40

Group type: COMPARATOR
Intervention: CPAP alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of CPAP and sildenafil
Number of subjects: 40
Study: 14499676

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG) instillations
Number of subjects: 487
Study: 11218623

Group type: EXPERIMENTAL
Intervention: Interferon + N-acetyl cysteine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 77
Study: 9112881

Group type: EXPERIMENTAL
Intervention: CO2-enriched water (1200 mg CO2 per kg water; immersion time, twenty minutes)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fresh water (immersion time, twenty minutes)
Number of subjects: 18
Study: 1589232

Group type: EXPERIMENTAL
Intervention: Naloxone (up to 8 mg in 20 ml vehicle)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both naloxone and saline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 20
Study: 3916511

Group type: EXPERIMENTAL
Intervention: Group I (azathioprine and prednisone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Group II (cyclosporine and prednisone)
Number of subjects: 32
Study: 31752938

Group type: EXPERIMENTAL
Intervention: Novel trauma score (0-14 points based on age, Glasgow Coma Scale, systolic blood pressure, and respiratory rate)
Number of subjects: 99767

Group type: COMPARATOR
Intervention: Revised Trauma Score (RTS)
Number of subjects: 99767

Group type: COMPARATOR
Intervention: Mechanism, Glasgow Coma Scale, Age, and Arterial Pressure (MGAP) score
Number of subjects: 99767
Study: 29453924

Group type: EXPERIMENTAL
Intervention: WHO criteria
Number of subjects: 520

Group type: COMPARATOR
Intervention: IADPSG criteria
Number of subjects: 520
Study: 25969342

Group type: EXPERIMENTAL
Intervention: Nurse-led case management intervention
Number of subjects: 12181

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 12181
Study: 25593907

Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP) administered two consecutive days twice a month
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) at a dosage of 3 mg/kg/day
Number of subjects: 20
Study: 22135107

Group type: EXPERIMENTAL
Intervention: Inferring word meanings with English feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inferring word meanings with German feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inferring word meanings with no feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Using marginal glosses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inferring word meanings with feedback in English vs. German
Number of subjects: 0
Study: 20562693

Group type: EXPERIMENTAL
Intervention: Plasma B-type natriuretic peptide and N-terminal fragment of its pro-hormone concentrations
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Higher plasma B-type natriuretic peptide and N-terminal fragment of its pro-hormone concentrations
Number of subjects: 1016
Study: 18557810

Group type: EXPERIMENTAL
Intervention: Upper limb botulinum toxin-A therapy (UL BTX-A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 16019553

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: EBVD (epirubicin instead of doxorubicin)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: MBVD (mitoxantrone instead of doxorubicin)
Number of subjects: 476
Study: 12066724

Group type: EXPERIMENTAL
Intervention: Dexamethasone 100 mg before induction of anaesthesia (group 1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 17
Study: 10520501

Group type: EXPERIMENTAL
Intervention: Somatostatin or its analogs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancreaticojejunostomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transient intubation of the Wirsung duct and mucosa-to-mucosa anastomosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occlusion of the residual stump
Number of subjects: 0
Study: 8952856

Group type: EXPERIMENTAL
Intervention: urokinase therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 1860787

Group type: EXPERIMENTAL
Intervention: Magnesium (Mg) pyrrolidone carboxylic acid 360 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6601463

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 31679621

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting cobalt-chromium stents (Co-Cr EESs) with 3 months of dual antiplatelet therapy
Number of subjects: 100
Study: 30515109

Group type: EXPERIMENTAL
Intervention: ACHIEVE behavioral weight loss intervention
Number of subjects: 0
Study: 26709542

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 4279

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 4279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4279
Study: 25480994

Group type: EXPERIMENTAL
Intervention: Xience V drug-eluting stent (DES; n = 48)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) postdilated with the SeQuent Please drug-eluting balloon (DEB; n = 41)
Number of subjects: 89
Study: 22424833

Group type: EXPERIMENTAL
Intervention: Intraocular injections of bevacizumab every 6 weeks for 6 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraocular injections of bevacizumab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 60
Study: 19281445

Group type: EXPERIMENTAL
Intervention: Glycaemic control intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard analysis plan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical assessment of outcome measures
Number of subjects: 0
Study: 18087554

Group type: EXPERIMENTAL
Intervention: Felodipine controlled release tablets with Hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine controlled release tablets with Metoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine controlled release tablets with Lisinopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine controlled release tablets alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine controlled release tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study: 16041734

Group type: EXPERIMENTAL
Intervention: Chi‐Ju‐Di‐Huang‐Wan with topical eye drops
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo with topical eye drops
Number of subjects: 80
Study: 11981646

Group type: EXPERIMENTAL
Intervention: Previn
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Phosphate buffer
Number of subjects: 56

Group type: COMPARATOR
Intervention: NaCl solutions of different osmolarities (0‐1200 mosmol/l)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 56
Study: 9459072

Group type: EXPERIMENTAL
Intervention: Nonsmoking partners
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Baseline quitters
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Partner smokers trying to quit
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Cessation interventions for expectant fathers
Number of subjects: 688

Group type: COMPARATOR
Intervention: Partner smoking status and partner support at baseline
Number of subjects: 688
Study: 7648940

Group type: EXPERIMENTAL
Intervention: Cisapride 5mg three times daily for 4 weeks
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study: 2655526

Group type: EXPERIMENTAL
Intervention: Naproxen (in addition to amoxicillin)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (in addition to amoxicillin)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 796486

Group type: EXPERIMENTAL
Intervention: Cephacetrile (CEC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cefazolin (CEZ)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 81
Study: 30584025

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1460
Study: 28625245

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 65
Study: 26028962

Group type: EXPERIMENTAL
Intervention: Tbo-filgrastim (5 μg/kg intravenous infusion)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg oral dose)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo (intravenous infusion)
Number of subjects: 145
Study: 23522488

Group type: EXPERIMENTAL
Intervention: 16 mg/m2 sagopilone over 3 h (treatment arm A)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 22 mg/m2 sagopilone over 0.5 h (treatment arm B)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 22 mg/m2 sagopilone over 3 h (treatment arm C)
Number of subjects: 128
Study: 21628724

Group type: EXPERIMENTAL
Intervention: Coordination visual biofeedback training for (re)learning preferred postural patterns
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no biofeedback training)
Number of subjects: 24
Study: 19361809

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 16731406

Group type: EXPERIMENTAL
Intervention: Etodolac, 600 mg, single dose preoperatively and 2 single doses of 600 mg on days 1 and 2 postoperatively
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexamethasone, 8 mg single dose preoperatively and 2 single doses of 4 mg on days 1 and 2 postoperatively
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 15545203

Group type: EXPERIMENTAL
Intervention: Isovolumetric detrusor pressure measured during a continuous occlusion test or a mechanical stop test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isovolumetric detrusor pressure estimated from a simple contractility index PIP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older indices (detrusor coefficient, projected isovolumetric pressure, bladder contractility index, detrusor power, contractility nomogram)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Watts factor
Number of subjects: 0
Study: 16285227

Group type: EXPERIMENTAL
Intervention: Combined-modality approaches with chemotherapy; specific agents not detailed; duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic multiagent chemotherapy for metastatic disease; specific agents not detailed; duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer cytotoxic drugs and biologically targeted agents; specific agents not detailed; duration not specified.
Number of subjects: 0
Study: 10492840

Group type: EXPERIMENTAL
Intervention: Pacing at a heart rate of 110 beats/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise to increase heart rate to about 110 beats/min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total QT shortening due to heart rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-heart rate-related QT interval shortening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in plasma catecholamine levels
Number of subjects: 0
Study: 9208572

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN) using liquid Ensure (Abbott‐Ross)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN, without glutamine)
Number of subjects: 24
Study: 2076406

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dinitrate isosorbide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine, Captopril, Dinitrate isosorbide
Number of subjects: 10
Study: 6768376

Group type: EXPERIMENTAL
Intervention: Pethidine 100 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Pentazocine 45 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Naloxone (200 microgram i.m.)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Repeated doses of pethidine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Pentazocine (more than one injection)
Number of subjects: 85
Study: 31971264

Group type: EXPERIMENTAL
Intervention: Straw phonation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vocal rest
Number of subjects: 25
Study: 30806186

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy in Bcl-2 negative patients
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy in Bcl-2 positive patients
Number of subjects: 247

Group type: COMPARATOR
Intervention: No chemotherapy in Bcl-2 positive patients
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Overall analysis including all patients
Number of subjects: 247
Study: 27353719

Group type: EXPERIMENTAL
Intervention: Sling exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sling + Swing stick flexible bar
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sling + Ball cushion
Number of subjects: 30
Study: 27631499

Group type: EXPERIMENTAL
Intervention: Seated t'ai chi exercise for 40 minutes three times a week for 26 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual exercise and entertainment activities
Number of subjects: 60
Study: 24733990

Group type: EXPERIMENTAL
Intervention: TAU plus psychotherapy (CBT‐I)
Number of subjects: 37

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 37
Study: 21948858

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 21058480

Group type: EXPERIMENTAL
Intervention: Quick meridian needling therapy plus scalp acupuncture (group A)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Conventional acupuncture (group B)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Scalp acupuncture (group C)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 147
Study: 17542201

Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Sonicare Elite)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Braun Oral‐B 3D Excel)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B 35)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no brushing)
Number of subjects: 40
Study: 15860385

Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin daily (group A, n = 20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (group B, n = 17)
Number of subjects: 37
Study: 12040335

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Noninvasive strategy
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 2457
Study: 9790003

Group type: EXPERIMENTAL
Intervention: Midazolam (0.35 mg/kg) and ketamine (5 mg/kg) (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Trimeprazine (3 mg/kg) and methadone (0.2 mg/kg) (Group B)
Number of subjects: 100
Study: 7674293

Group type: EXPERIMENTAL
Intervention: Harassment condition
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Social Evaluation condition
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Social Evaluation and Harassment conditions
Number of subjects: 183
Study: 2551537

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin) for 5-10 days
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard heparin (continuous intravenous heparin)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 194